Authors’ Reply to Krebs-Brown et al. Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”

Detalles Bibliográficos
Autores principales: Concordet, D., Gandia, P., Montastruc, J. L., Bousquet-Mélou, A., Lees, P., Ferran, A. A., Toutain, P. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007435/
https://www.ncbi.nlm.nih.gov/pubmed/31802401
http://dx.doi.org/10.1007/s40262-019-00848-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007435/
https://www.ncbi.nlm.nih.gov/pubmed/31802401
http://dx.doi.org/10.1007/s40262-019-00848-z

Ejemplares similares